Comparative Pharmacology
Head-to-head clinical analysis: ADCIRCA versus FINASTERIDE AND TADALAFIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADCIRCA versus FINASTERIDE AND TADALAFIL.
ADCIRCA vs FINASTERIDE AND TADALAFIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phosphodiesterase-5 (PDE5) inhibitor; increases cGMP in pulmonary vascular smooth muscle, leading to vasodilation.
Finasteride is a 5α-reductase inhibitor that inhibits conversion of testosterone to dihydrotestosterone (DHT). Tadalafil is a phosphodiesterase-5 (PDE5) inhibitor that enhances nitric oxide-mediated vasodilation by increasing cyclic guanosine monophosphate (cGMP) in smooth muscle.
10 mg orally three times daily.
One capsule containing finasteride 5 mg and tadalafil 5 mg orally once daily.
None Documented
None Documented
Terminal half-life: 10–15 hours in healthy adults; prolonged in hepatic impairment (Child-Pugh B/C: up to 30 hours); clinical context: supports twice-daily dosing
Finasteride: 6-8 hours (elderly ~8 hours); Tadalafil: 17.5 hours (enables once-daily dosing).
Renal: ~70% (metabolites and unchanged drug), Fecal: ~20%, Biliary: minor
Finasteride: 57% feces, 39% urine (metabolites); Tadalafil: 36% urine, 61% feces (mostly metabolites).
Category C
Category A/B
PDE5 Inhibitor
PDE5 Inhibitor